Clinical Trial Update: Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY [Phase 2]

View source ↗

Summary

Phase II multicenter open-label single-arm study of pembrolizumab in marginal zone lymphoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: University of Ulm | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2026-02-27